Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Theragen Unveils Real-World Evidence at SMISS 2026 Identifying Predictors of Recovery Following Spinal Fusion with ActaStim-S: As presented at the SMISS 2026 Annual Forum and reported by OrthoSpineNews, machine learning models of nearly 7,000 patients revealed that daily bone growth stimulator adherence is the strongest modifiable predictor of pain reduction following spinal fusion, plateauing around 13 hours per day.
• OrthoPediatrics Surpasses 1,000 Implantations of the Pediatric Nailing Platform Tibia System: Reported by OrthoSpineNews, OrthoPediatrics reached a clinical milestone of 1,000 implantations of its Pediatric Nailing Platform (PNP) Tibia System, featuring the market's only 7mm cannulated rigid tibial nail designed specifically for pediatric and adolescent fracture stabilization.
• Enovis Expands AAOS Partnership as First Multi-Registry Industry Sponsor Supporting AJRR and Shoulder & Elbow Registry Through 2027: As detailed in Orthopedics This Week, Enovis expanded its AAOS Registry Program sponsorship to become the first industry partner supporting multiple clinical registries, committing to the Shoulder & Elbow Registry (SER) alongside the AJRR through 2027.
• MicroPort EVOLUTION MPX™ Total Knee System Cleared: Suzhou Microport Orthorecon Co., Ltd. obtained FDA 510(k) clearance (K262293) for the EVOLUTION MPX™ Total Knee System indicated for medial-pivot total knee arthroplasty.
• Innovasis Porous Titanium Interbody Fusion Systems Cleared: INNO Holdings Inc. DBA Innovasis received FDA 510(k) clearance (K262025) for its AxTiHA® Stand-Alone ALIF, TxTiHA® IBF, and HAtetracell®-C Titanium Cervical IBF hydroxyapatite-coated porous titanium systems.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

Theragen — Theragen Unveils Real-World Evidence at SMISS 2026 Identifying Predictors of Recovery Following Spinal Fusion with ActaStim-S

• Summary: Theragen announced longitudinal clinical findings from nearly 7,000 patients and 200,000 recovery days at the SMISS 2026 Annual Forum. Machine learning models (SHAP and XGBoost) demonstrated that bone growth stimulator daily wear adherence is the strongest modifiable predictor of clinically meaningful pain improvement following spinal fusion, with therapeutic benefit increasing linearly up to approximately 13 hours daily before plateauing.
• Key Details:
  • Device/System Name: ActaStim®-S Bone Growth Stimulator
  • Status: Clinical Evidence / Real-World Registry Study (SMISS 2026 Forum)
  • Clinical Significance: Equips spine surgeons with objective wear benchmarks (approx. 13 hours/day) and identifies high-risk cohorts—such as multilevel or TLIF procedures—enabling early, targeted adherence counseling to optimize fusion arthrodesis and minimize persistent postoperative pain.
• Original Source: OrthoSpineNews

Trauma & Extremities

OrthoPediatrics Corp. — OrthoPediatrics Surpasses 1,000 Implantations of the Pediatric Nailing Platform Tibia System

• Summary: OrthoPediatrics Corp. announced the completion of the 1,000th clinical implantation of its Pediatric Nailing Platform (PNP) Tibia System. Engineered specifically to resolve a critical void in pediatric trauma care, the platform provides rigid intramedullary stabilization across nail diameters from 7mm to 12mm, with the unique 7mm size accounting for nearly 20% of all clinical implantations to date.
• Key Details:
  • Device/System Name: Pediatric Nailing Platform (PNP) Tibia System
  • Status: Commercial Clinical Milestone (>1,000 Implantations)
  • Clinical Significance: Provides pediatric orthopaedic surgeons with rigid intramedullary fixation tailored to pediatric anatomy, offering physis-sparing proximal and distal locking options alongside dedicated instrumentation supporting both traditional infrapatellar and suprapatellar approaches.
• Original Source: OrthoSpineNews

Corporate, M&A & Regulatory

Enovis — Enovis Expands AAOS Partnership as First Multi-Registry Industry Sponsor Supporting AJRR and Shoulder & Elbow Registry Through 2027

• Summary: The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis has expanded its commitment to the AAOS Registry Program, becoming the first industry partner to sponsor multiple national registries. In addition to its multi-year support of the American Joint Replacement Registry (AJRR), Enovis will sponsor the Shoulder & Elbow Registry (SER) through 2027 as the registry introduces implant component-level data.
• Key Details:
  • Device/System Name: AAOS Registry Program (AJRR & Shoulder and Elbow Registry)
  • Status: Multi-Registry Sponsorship Expansion (Through 2027)
  • Clinical Significance: Accelerates real-world evidence generation in upper extremity arthroplasty, empowering surgeons and researchers with multi-institutional component-level analytics to evaluate clinical survival, implant design efficacy, and revision patterns across shoulder and elbow procedures.
• Original Source: Orthopedics This Week

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.